In Vitro Antiviral Activity of Two Host Defense Peptides Against Human alphaherpesvirus 1

IF 2 4区生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY International Journal of Peptide Research and Therapeutics Pub Date : 2024-03-18 DOI:10.1007/s10989-024-10597-8

Gisele Regina Rodrigues, Rhayfa Lorrayne Araujo Berlanda, Liana Costa Pereira Vilas Boas, Lídia Maria Pinto de Lima, Octávio Luiz Franco

{"title":"In Vitro Antiviral Activity of Two Host Defense Peptides Against Human alphaherpesvirus 1","authors":"Gisele Regina Rodrigues, Rhayfa Lorrayne Araujo Berlanda, Liana Costa Pereira Vilas Boas, Lídia Maria Pinto de Lima, Octávio Luiz Franco","doi":"10.1007/s10989-024-10597-8","DOIUrl":null,"url":null,"abstract":"Viral infections are continually emerging with new characteristics and the potential to cause outbreaks or pandemics. Therefore, identification of new antiviral compounds is extremely necessary for therapeutic. This study aimed to evaluate the in vitro action of host defense peptides against Human alphaherpesvirus 1 (HHV-1) replication. Vero cell monolayers were infected with HHV-1 TCID50 and treated with different concentrations of IDR-1018 and DJK-6. The cell viability was evaluated by MTT method. Time of addition assays were performed to infer the effect of peptides upon the viral replicative cycle. IDR-1018 and DJK-6 were able to inhibit the HHV-1 replication in maximum nontoxic concentrations. However, IDR-1018 presented higher potency and a better safety profile. In addition, IDR-1018 probably inhibits adhesion, entry and post entry of virus infection. DJK-6 seems to be capable of interfering with virus entry and viral biosynthesis.","PeriodicalId":14217,"journal":{"name":"International Journal of Peptide Research and Therapeutics","volume":"26 1","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Peptide Research and Therapeutics","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s10989-024-10597-8","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Viral infections are continually emerging with new characteristics and the potential to cause outbreaks or pandemics. Therefore, identification of new antiviral compounds is extremely necessary for therapeutic. This study aimed to evaluate the in vitro action of host defense peptides against Human alphaherpesvirus 1 (HHV-1) replication. Vero cell monolayers were infected with HHV-1 TCID₅₀ and treated with different concentrations of IDR-1018 and DJK-6. The cell viability was evaluated by MTT method. Time of addition assays were performed to infer the effect of peptides upon the viral replicative cycle. IDR-1018 and DJK-6 were able to inhibit the HHV-1 replication in maximum nontoxic concentrations. However, IDR-1018 presented higher potency and a better safety profile. In addition, IDR-1018 probably inhibits adhesion, entry and post entry of virus infection. DJK-6 seems to be capable of interfering with virus entry and viral biosynthesis.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

两种宿主防御肽对人α疱疹病毒 1 的体外抗病毒活性

病毒感染不断出现新的特征，并有可能导致疾病爆发或大流行。因此，鉴定新的抗病毒化合物对治疗极为必要。本研究旨在评估宿主防御肽对人α疱疹病毒1（HHV-1）复制的体外作用。用 TCID50 的 HHV-1 感染 Vero 细胞单层，并用不同浓度的 IDR-1018 和 DJK-6 处理。用 MTT 法评估细胞活力。进行添加时间测定以推断多肽对病毒复制周期的影响。IDR-1018和DJK-6能以最大无毒浓度抑制HHV-1的复制。不过，IDR-1018 的效力更高，安全性更好。此外，IDR-1018 可能会抑制病毒感染的粘附、进入和后进入。DJK-6 似乎能够干扰病毒的进入和病毒的生物合成。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Journal of Peptide Research and Therapeutics 生物-生化与分子生物学

CiteScore

5.50

自引率

8.00%

发文量

131

审稿时长

>12 weeks

期刊介绍： The International Journal for Peptide Research & Therapeutics is an international, peer-reviewed journal focusing on issues, research, and integration of knowledge on the latest developments in peptide therapeutics. The Journal brings together in a single source the most exciting work in peptide research, including isolation, structural characterization, synthesis and biological activity of peptides, and thereby aids in the development of unifying concepts from diverse perspectives. The Journal invites substantial contributions in the following thematic areas: -New advances in peptide drug delivery systems. -Application of peptide therapeutics to specific diseases. -New advances in synthetic methods. -The development of new procedures for construction of peptide libraries and methodology for screening of such mixtures. -The use of peptides in the study of enzyme specificity and mechanism, receptor binding and antibody/antigen interactions -Applications of such techniques as chromatography, electrophoresis, NMR and X-ray crystallography, mass spectrometry.